Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren Lasko(AbbVie (United States)), Kenneth D. Bromberg(AbbVie (United States)), Vlasios Manaves(AbbVie (United States)), Chunaram Choudhary(Novo Nordisk Foundation), Philip A. Cole(Brigham and Women's Hospital), Bailin Shaw(AbbVie (United States)), David McElligott(Japan Proton Accelerator Research Complex), Robin R. Frey(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), T. Matt Hansen(AbbVie (United States)), Lloyd T. Lam(National Institutes of Health), Tamar Uziel(AbbVie (United States)), Wei Qiu(Nanfang Hospital), Albert Lai(AbbVie (United States)), Kannan R. Karukurichi(Faculty of 1000 (United States)), Clarissa G. Jakob(AbbVie (United States)), Michael A. Patane(IIT@MIT), Debra C. Ferguson(AbbVie (United States)), John H. Van Drie(Andover Eye Associates), Ruth L. Martin(AbbVie (United States)), Ronen Marmorstein(University of Pennsylvania), Arthur F. Kluge, Paul Hessler(AbbVie (United States)), Emily J. Faivre(AbbVie (United States)), Gary G. Chiang(Therapeutics Clinical Research), Enrico L. DiGiammarino(AbbVie (United States)), Rohinton Edalji(AbbVie (United States)), Brian T. Weinert(University of Copenhagen), Roberto M. Risi(AbbVie (United States)), Ce Wang(Hubei Academy of Agricultural Sciences), Michael R. Michaelides(AbbVie (United States)), Maricel Torrent(United States Military Academy), Peter de Vries(International Therapeutics (United States)), Debra Montgomery(AbbVie (United States)), J. William Langston(Faraday Technology (United States)), Saul H. Rosenberg(Abbott Fund), Mikkel A. Algire(AbbVie (United States)), Ed Kesicki(Faculty of 1000 (United States)), Chaohong Sun(AbbVie (United States))
Cited by 853
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
|Cell|2006|1.6k
Requirement of the MRN complex for ATM activation by DNA damage
|The EMBO Journal|2003|1.1k